Alzheimer's Association International Conference (AAIC)

July 27-31, 2020 | Virtual

International investigators, clinicians, and care researchers will come together online for AAIC 2020 to discuss the latest studies, theories, and discoveries that will help bring the world closer to breakthroughs in dementia science.

_________________________________________________________________________________________________________
 

QUANTERIX PRODUCT THEATER PRESENTATION: 

Tatiana Plavina, PhD, Quanterix VP, Clinical Strategy
Take a deep dive into the new Simoa p-tau181 blood immunoassay and be among the first to learn about our newest multiplex neurology kit targeted for Alzheimer's research!

Access Video On-Demand!

_________________________________________________________________________________________________________

SPOTLIGHT ON QUANTERIX POSTERS AND PRESENTATION AT THIS YEAR'S EVENT:

Tuesday, July 28, 2020
12:00 am - 11:59 pm EDT

Poster #43506

Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood

Poster #41238

An ultrasensitive immunoassay for detection of p-tau181 in blood

ACCESS DOWNLOADABLE POSTERS

 

ORAL PRESENTATION:

A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer’s disease: the first results.
 

Session Chatroom: 7:30 AM - 7:55 AM (US Central Time), July 28

_________________________________________________________________________________________________________

LISTING OF POSTER AND PRESENTATION ABSTRACTS FEATURING SIMOA TECHNOLOGY AT AAIC:

Serum neurofilament light and whole brain volume associate with machine-learning derived brain-predicted age in the British 1946 Birth Cohort.

Wagen, et al

Association between plasma neurofilament light chain levels and cognition in early Parkinson's Disease

Yong, et al

CSF phosphorylated tau-217 is increased in Alzheimer’s and Creutzfeldt-Jakob diseases, and correlates with amyloid pathology

Emeršič, et al

Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals

den Braberm et al

Plasma-based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease

Leuzy, et al

Plasma phospho-tau181 in over 400 cognitively healthy 69 to 71-year-olds: associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study

Keshavan, et al

Plasma Tau is Negatively Correlated with Frontal Lobe CBF in Hypertensive Adults on the AD Spectrum

Swinford, et al

Association of Plasma Abeta and Tau levels in relation to cognition and brain structure in a diverse community

DeCarli, et al

The effect of APOE ɛ4 in Alzheimer’s disease biomarkers in Down syndrome

Vilaplana, et al

Serum Neurofilament Light in memory clinic practice

Willemse, et al

Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer’s disease

Baldacci, et al

Tracking neurodegeneration in frontotemporal dementia and Alzheimer’s disease: a comparative study of plasma Tau and neurofilament light chain

Illán-Gala, et al

Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: the SCIENCe project.

Verberk, et al

A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer’s disease: the first results.

Verberk, et al

1H-MRS signature in Alzheimer disease in Down syndrome.

Barroeta, et al

Level of plasma tau and depression, anxiety and worry in cognitively normal older adults

Hall, et al

Plasma levels of an N-terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly

Chhatwal, et al

Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease

Chong, et al

Quantifying the synaptic vesicle-associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimer’s disease

Goossens, et al

Plasma p-tau immunoassays, methodological aspects and clinical performance

Blennow, et al

BDNF-Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: the SCIENCe project.

van den Bosch, et al

Elevated plasma neurofilament light (NfL) is associated with incident Alzheimer’s disease and accelerated cognitive decline in adults with Down Syndrome

Dang, et al

Plasma biomarkers Aβ42, Aβ40, and tau in Down Syndrome Dementia.

Honig, et al

Serum neurofilament light level in the clinical diagnosis of Chinese patients with Alzheimer’s Disease

Chu, et al

Plasma Neurofilament Light Chain (NfL) is Differentially Associated with Neuropsychological Test Performance among Non-Hispanic Whites and Hispanic, Mexican Americans: An HABLE Study.

Petersen, et al

Anterolateral entorhinal cortical thinning as a biomarker for Alzheimer’s disease in Down syndrome

Sathishkumar, et al

Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology

Ashton, et al

VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer’s disease

Belbin, et al

Peripheral Neurofilament Light Chain (NFL) level Predicts the Two-year Outcome of Amnestic Mild Cognitive Impairment in Chinese Han Population

Zhao, et al

Evaluation of extracellular vesicles isolated from the cerebrospinal fluid and plasma from former national football League players at a risk for chronic traumatic encephalopathy

Muraoka, et al

A new biological assay of Aβ clearance - the Aβ mid domain immunoassay

Torsetnes, et al

Correlation between cerebrospinal fluid and blood neurofilament light protein: A systematic review and meta-analysis

von Widekind, et al

Pathological significance of neuron-derived EVs in Alzheimer's disease and its potential as biomarkers

Kudo, et al

Potosaccharide treatment showed efficacy on hyperactivity, learning and memory and neurofilament light chain (NfL) plasma level in APPSwDI/NOS2-/- (CVN) mouse model of Alzheimer´s Disease.

Switzer, et al

Peripapillary retinal nerve fiber layer thickness measured using optical coherence tomography as a marker of Alzheimer's disease

Wang, et al

An ultrasensitive immunoassay for detection of p-tau181 in blood

Chen, et al

Translational potential of mouse CSF biomarkers in Alzheimer’s disease - association of CSF neurogranin with tau, NFL and amyloid pathology in App knock-in mouse models

Smailovic, et al

Longitudinal plasma levels of Neurofilament light in Down syndrome: a multicenter study

Alcolea, et al

Peripheral Neurofilament Light Chain (NFL) level Predicts the Two-year Outcome of Amnestic Mild Cognitive Impairment in Chinese Han Population

Zhao, et al

Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD)

Heuer, et al

Associations between subjective cognitive decline (SCD) diagnosis and severity with plasma tau and NfL levels using SIMOA technology

Azad, et al

Latent disease models estimate symptom onset in familial frontotemporal lobar degeneration and enable novel designs for early-stage clinical trials

Staffaroni, et al

Fluid-Based Biomarkers to Facilitate Clinical Trial Execution and Interpretation

Zetterberg, et al

Plasma p-tau immunoassays, methodological aspects and clinical performance

Blennow, et al

Biomarkers and Trial-Ready Cohorts for Alzheimer’s disease Clinical Trials in the Down Syndrome Population

Fortea, et al

Gantnerumab In-depth Outcomes

Salloway, et al

Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood

Shan, et al

Plasma phospho-tau in familial Alzheimer’s disease

O'Connor, et al

Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls

Kvartsberg, et al

Association between plasma neurofilament light chain levels and cognition in early Parkinson's Disease

Yong, et al

Predicting development of AD clinical symptoms and their progression through a collection of novel plasma Aβ immunoassays

Liu, et al

Potosaccharide treatment showed efficacy on hyperactivity, learning and memory and neurofilament light chain (NfL) plasma level in APPSwDI/NOS2-/- (CVN) mouse model of Alzheimer´s Disease.

Switzer, et al

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

Rodriguez, et al

Quantification of Neurological Blood Based Biomarkers in Critically Ill Patients with COVID-19 

Cooper, et al

AL001 restores CSF PGRN levels and normalizes disease-associated biomarkers in individuals with frontotemporal dementia due to heterozygous mutations in the progranulin gene       
Haynes, et al

Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard
Simrén, et al

Evaluating Vascular Cognitive Impairment and Dementia Due to Small-Vessel Disease Using Plasma Levels of PLGF and VEGFA
Winder, et al

MORE CONFERENCE INFORMATION

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more